---
layout: default
title: Rasagiline
parent: 僅模型預測 (L5)
nav_order: 58
evidence_level: L5
indication_count: 6
---

# Rasagiline
{: .fs-9 }

證據等級: **L5** | 預測適應症: **6** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Rasagiline: Repurposing Assessment — Incomplete Evidence Pack

## One-Sentence Summary

Rasagiline (DrugBank ID: DB01367) is a candidate flagged for drug repurposing analysis, however the current Evidence Pack contains **no predicted new indications**, **no original indication data**, and **no mechanism of action information**. With three blocking or high-severity data gaps unresolved, a substantive repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not yet available; no supporting studies |
| Germany Market Status | ✗ Not marketed (0 authorisations) |
| Number of Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on the Evidence Pack received, Rasagiline (DB01367) has no original indication recorded and no TxGNN-predicted repurposing target has been generated. Without a predicted indication, it is not possible to evaluate mechanistic plausibility, disease-pathway overlap, or translational rationale at this time.

The absence of predicted indications is most likely attributable to missing upstream inputs: the `meta.inputs_received` field records only `"drugbank"` as a completed data source, suggesting that the knowledge-graph embedding or TxGNN inference step has not yet been executed against a complete input set.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is structurally incomplete — predicted indications, original indication text, and mechanism of action are all absent, leaving no repurposing hypothesis to evaluate. No clinical trial or literature search can be meaningfully scoped without a target indication.

**To proceed, the following is needed:**

1. **Resolve DG002 (High) — Mechanism of Action:** Query DrugBank API for DB01367 to populate `original_moa`. This is required before mechanistic plausibility can be assessed.
2. **Resolve DG001 (Blocking) — Package Insert Warnings/Contraindications:** Download and parse the TFDA or BfArM package insert PDF to populate safety fields. This blocks the S1 safety screen.
3. **Re-run TxGNN inference:** The `predicted_indications` array is empty. Verify that the KG embedding, DL prediction, and disease-mapping pipeline steps (Phase 2 per project SOP) have been executed for DB01367. Re-trigger the pipeline with a complete input set.
4. **Populate `original_indications`:** Confirm the approved indication(s) from the DrugBank record or regulatory source and backfill the field so the report title and Quick Overview can be completed.
5. **Re-generate this report** once the above gaps are resolved and `predicted_indications[0]` is populated.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

